Heparan sulfate domains on cultured activated glomerular endothelial cells mediate leukocyte trafficking

Kidney International

Volumn 73, Issue 1, 2008, Pages 52-62

  Rops, A L ^a   Van Den Hoven, M J ^a   Baselmans, M M ^a   Lensen, J F ^a   Wijnhoven, T J ^a,b   Van Den Heuvel, L P ^b   Van Kuppevelt, T H ^a   Berden, J H ^a   Van Der Vlag, J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adhesion; Glomerular endothelium; Heparan sulfate; Inflammation; Leukocyte

Indexed keywords

AGRIN; CD11B ANTIGEN; COLLAGEN TYPE 18; CYTOKINE; ENDOSTATIN; GLYPICAN 1; HEPARAN SULFATE; HEPARANASE; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; L SELECTIN; PERLECAN; SYNDECAN 1; SYNDECAN 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; GENE EXPRESSION; GLOMERULUS BASEMENT MEMBRANE; KIDNEY CELL CULTURE; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; LEUKOCYTE ROLLING; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SULFATION;

EID: 37249038716     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002573     Document Type: Article

References (56)

1. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991; 67: 1033-1036.
2. Schlondorff D, Nelson PJ, Luckow B et al. Chemokines and renal disease. Kidney Int 1997; 51: 610-621.
3. Rops AL, van der Vlag J, Lensen JF et al. Heparan sulfate proteoglycans in glomerular inflammation. Kidney Int 2004; 65: 768-785.
4. Parish CR. Heparan sulfate and inflammation. Nat Immunol 2005; 6: 861-862.
5. Taylor KR, Gallo RL. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J 2006; 20: 9-22.
6. Esko JD, Selleck SB. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem 2002; 71: 435-471.
7. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 1998; 67: 609-652.
8. Okada Y, Yamada S, Toyoshima M et al. Structural recognition by recombinant human heparanase that plays critical roles in tumor metastasis. Hierarchical sulfate groups with different effects and the essential target disulfated trisaccharide sequence. J Biol Chem 2002; 277: 42488-42495.
9. Pikas DS, Li JP, Vlodavsky I et al. Substrate specificity of heparanases from human hepatoma and platelets. J Biol Chem 1998; 273: 18770-18777.
10. Wang S, Ai X, Freeman SD et al. QSulf1, a heparan sulfate 6-O-endosulfatase, inhibits fibroblast growth factor signaling in mesoderm induction and angiogenesis. Proc Natl Acad Sci USA 2004; 101: 4833-4838.
11. Uchimura K, Morimoto-Tomita M, Bistrup A et al. HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1. BMC Biochem 2006; 7: 2.
12. Lever R, Page CP. Novel drug development opportunities for heparin. Nat Rev Drug Discov 2002; 1: 140-148.
13. Kuschert GS, Coulin F, Power CA et al. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 1999; 38: 12959-12968.
14. Carter NM, Ali S, Kirby JA. Endothelial inflammation: the role of differential expression of N-deacetylase/N-sulphotransferase enzymes in alteration of the immunological properties of heparan sulphate. J Cell Sci 2003; 116: 3591-3600.
15. Koenig A, Norgard-Sumnicht K, Linhardt R et al. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998; 101: 877-889.
16. Giuffre L, Cordey AS, Monai N et al. Monocyte adhesion to activated aortic endothelium: role of L-selectin and heparan sulfate proteoglycans. J Cell Biol 1997; 136: 945-956.
17. Li YF, Kawashima H, Watanabe N et al. Identification and characterization of ligands for L-selectin in the kidney. II. Expression of chondroitin sulfate and heparan sulfate proteoglycans reactive with L-selectin. FEBS Lett 1999; 444: 201-205.
18. Kawashima H, Watanabe N, Hirose M et al. Collagen XVIII, a basement membrane heparan sulfate proteoglycan, interacts with L-selectin and monocyte chemoattractant protein-1. J Biol Chem 2003; 278: 13069-13076.
19. Celie JW, Keuning ED, Beelen RH et al. Identification of L-selectin binding heparan sulfates attached to collagen type XVIII. J Biol Chem 2005; 280: 26965-26973.
20. Watanabe N, Kawashima H, Li YF et al. Identification and characterization of ligands for L-selectin in the kidney. III. Characterization of L-selectin reactive heparan sulfate proteoglycans. J Biochem (Tokyo) 1999; 125: 826-831.
21. Wang L, Brown JR, Varki A et al. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 2002; 110: 127-136.
22. Wang L, Fuster M, Sriramarao P et al. Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol 2005; 6: 902-910.
23. Diamond MS, Alon R, Parkos CA et al. Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1). J Cell Biol 1995; 130: 1473-1482.
24. Gautam N, Olofsson AM, Herwald H et al. Heparin-binding protein (HBP/CAP37): a missing link in neutrophil-evoked alteration of vascular permeability. Nat Med 2001; 7: 1123-1127.
25. Bartlett MR, Underwood PA, Parish CR. Comparative analysis of the ability of leucocytes, endothelial cells and platelets to degrade the subendothelial basement membrane: evidence for cytokine dependence and detection of a novel sulfatase. Immunol Cell Biol 1995; 73: 113-124.
26. Vlodavsky I, Eldor A, Haimovitz-Friedman A et al. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 1992; 12: 112-127.
27. Kojima T, Leone CW, Marchildon GA et al. Isolation and characterization of heparan sulfate proteoglycans produced by cloned rat microvascular endothelial cells. J Biol Chem 1992; 267: 4859-4869.
28. Lindblom A, Bengtsson-Olivecrona G, Fransson LA. Domain structure of endothelial heparan sulphate. Biochem J 1991; 279(Part 3): 821-829.
29. Hiscock DR, Canfield A, Gallagher JT. Molecular structure of heparan sulphate synthesised by bovine aortic endothelial cells. Biochim Biophys Acta 1995; 1244: 104-112.
30. van den Heuvel LP, van den Born J, van de Velden TJ et al. Isolation and partial characterization of heparan sulphate proteoglycan from the human glomerular basement membrane. Biochem J 1989; 264: 457-465.
31. Raats CJ, Bakker MA, Hoch W et al. Differential expression of agrin in renal basement membranes as revealed by domain-specific antibodies. J Biol Chem 1998; 273: 17832-17838.
32. Hassell JR, Robey PG, Barrach HJ et al. Isolation of a heparan sulfate-containing proteoglycan from basement membrane. Proc Natl Acad Sci USA 1980; 77: 4494-4498.
33. Smetsers TF, van de Westerlo EM, ten Dam GB et al. Human single-chain antibodies reactive with native chondroitin sulfate detect chondroitin sulfate alterations in melanoma and psoriasis. J Invest Dermatol 2004; 122: 707-716.
34. Kurup S, Wijnhoven TJ, Jenniskens GJ et al. Characterization of anti-heparan sulfate phage-display antibodies AO4B08 and HS4E4. J Biol Chem 2007; 282: 21032-21042.
35. van Kuppevelt TH, Dennissen MA, van Venrooij WJ et al. Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney. J Biol Chem 1998; 273: 12960-12966.
36. van de Westerlo EM, Smetsers TF, Dennissen MA et al. Human single chain antibodies against heparin: selection, characterization, and effect on coagulation. Blood 2002; 99: 2427-2433.
37. David G, Bai XM, Van der Schueren B et al. Developmental changes in heparan sulfate expression: in situ detection with mAbs. J Cell Biol 1992; 119: 961-975.
38. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004; 3: 17-26.
39. Madge LA, Pober JS. TNF signaling in vascular endothelial cells. Exp Mol Pathol 2001; 70: 317-325.
40. Rops AL, van den Hoven MJ, Bakker MA et al. Expression of glomerular heparan sulphate domains in murine and human lupus nephritis. Nephrol Dial Transplant 2007; 22: 1891-1902.
41. Rops AL, Götte M, Baselmans MH et al. Syndecan-1 deficiency aggravates anti-GBM nephritis. Kidney Int 2007; doi:10.1038/sj.ki. 5002514.
42. Edovitsky E, Lerner I, Zcharia E et al. Role of endothelial heparanase in delayed-type hypersensitivity. Blood 2006; 107: 3609-3616.
43. Roghani M, Mansukhani A, Dell'Era P et al. Heparin increases the affinity of basic fibroblast growth factor for its receptor but is not required for binding. J Biol Chem 1994; 269: 3976-3984.
44. Guchhait P, Tosi MF, Smith CW et al. The murine myeloid cell line 32Dcl3 as a model system for studying neutrophil functions. J Immunol Methods 2003; 283: 195-204.
45. Kevil CG, Chidlow JH, Bullard DC et al. High-temporal-resolution analysis demonstrates that ICAM-1 stabilizes WEHI 274.1 monocytic cell rolling on endothelium. Am J Physiol Cell Physiol 2003; 285: C112-C118.
46. Linhardt RJ, Loganathan D, al-Hakim A et al. Oligosaccharide mapping of low molecular weight heparins: structure and activity differences. J Med Chem 1990; 33: 1639-1645.
47. Rops AL, Jacobs CW, Linssen PC et al. Heparan sulfate on activated glomerular endothelial cells and exogenous heparinoids influence the rolling and adhesion of leucocytes. Nephrol Dial Transplant 2007; 22: 1070-1077.
48. Sorensson J, Bjornson A, Ohlson M et al. Synthesis of sulfated proteoglycans by bovine glomerular endothelial cells in culture. Am J Physiol Renal Physiol 2003; 284: F373-F380.
49. Kato M, Wang H, Kainulainen V et al. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med 1998; 4: 691-697.
50. Rizea Savu S, Silvestro L. Adhesion inhibition 'in vitro' by heparin derivatives correlates with their activity on angiogenesis in mice. J Cell Mol Med 2003; 7: 187-191.
51. Ledin J, Staatz W, Li JP et al. Heparan sulfate structure in mice with genetically modified heparan sulfate production. J Biol Chem 2004; 279: 42732-42741.
52. Rops AL, van der Vlag J, Jacobs CW et al. Isolation and characterization of conditionally immortalized mouse glomerular endothelial cell lines. Kidney Int 2004; 66: 2193-2201.
53. van Setten PA, van Hinsbergh VW, van der Velden TJ et al. Effects of TNF alpha on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. Kidney Int 1997; 51: 1245-1256.
54. Ni N, Kevil CG, Bullard DC et al. Avidity modulation activates adhesion under flow and requires cooperativity among adhesion receptors. Biophys J 2003; 85: 4122-4133.
55. Middleton MM, Campbell PA. Functions of purified mouse neutrophils isolated from gelatin sponges. J Leukoc Biol 1989; 46: 461-466.
56. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 1986; 883: 173-177.